Navigation Links
PCa markers improve predictive performance of existing clinical variables
Date:3/18/2013

Milan, 15 March 2013 A genetic score based on PCa risk-associated single nucleotide polymorphisms (SNPs) is an independent predictor of prostate biopsy outcomes, suggest the results of a new study conducted by a group from the Department of Urology Huashan Hospital, Fudan University in Shanghai, China.

The authors, who relate their findings to the male population in China, also suggest that this score can improve predictive performance of existing clinical variables, especially for patients with a total PSA levels < 20 ng/ml

"Genetic susceptibility to prostate cancer (PCa) is well established," write the authors. "In a recent study with a large number of cases and controls from the Chinese Consortium for PCa Genetics (ChinaPCa), we identified 25 SNPs that were significantly associated with PCa risk and obtained odds ratio (OR) estimates for these SNPs in Chinese men."

In the follow-up of the ChinaPCa study, this investigation aimed to evaluate whether a genetic score based on these 25 PCa risk-associated SNPs can independently predict outcome of prostate biopsy, and improve the predictive performance of existing clinical variables such as prostate-specific antigen (PSA).

The results of the study will be presented at the 28th Annual EAU Congress in Milan, 15-19 March 2013.

Three-hundreds and twelve consecutive patients who underwent prostate biopsy for detection of PCa at Huashan Hospital, Shanghai, China since January 2010 were recruited for this study. All clinical variables such as serum PSA levels as well as DNA samples from peripheral blood were collected prior to biopsy. Twenty-five SNPs were genotyped using the Sequenom MassARRAY platform.

In the course of the study, a genetic score was calculated for each man based on his genotype at the 25 SNPs and weighted by OR obtained from the ChinaPCa study. Multivariate analyses were performed to test association of biopsy outcome and predictors (clinical variables and genetic score) using a logistic regression model. Area under the receiver operating characteristic curve (AUC) was used to assess the ability of clinical variables and the genetic score to predict for positive prostate biopsy. Detection rate of PCa was also used to assess performance of predictors.

The results of the study revealed that the PCa detection rate was 45% overall in this biopsy cohort, and was 29% and 79%, respectively for patients with total PSA levels =20 ng/ml (~1/3 of patients). Age, total PSA levels, and genetic score were independent predictors of biopsy outcomes, P = 0.002, 7.18 x 10-9, and 0.01, respectively.

The AUC for discriminating biopsy outcomes was 0.65, 0.79, and 0.66, respectively for age, total PSA, and genetic score. When genetic score was added to the model with age and total PSA, the AUC for discriminating biopsy outcomes increased from 0.82 to 0.86. The difference in AUC was statistically significant, P < 0.05. For patients with total PSA levels 1.5.


'/>"/>

Contact: Ivanka Moerkerken
i.moerkerken@uroweb.org
31-026-389-0680
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Trio of biomarkers may help identify kidney cancer in early stages
2. Biomarkers may help predict progression of Barretts esophagus to esophageal adenocarcinoma
3. Mayo Clinic-led study identifies biomarkers for early risk assessment of acute kidney injury
4. NIH launches collaborative effort to find biomarkers for Parkinsons
5. Smoking intensity and cancer markers predict seriousness of bladder cancer
6. New markers could improve treatment and survival in acute lymphoblastic leukaemia
7. Kentucky team inhibits Alzheimers biomarkers in animal model by targeting astrocytes
8. Metabolic biomarkers for preventive molecular medicine
9. Tracking down smallest biomarkers
10. Biomarkers of behavior, therapeutic targets for adult B-acute lymphoblastic leukemia identified
11. Genetic markers for testosterone and estrogen level regulation identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO has ... personnel have a basic understanding of the techniques they use so they can ... help them reduce waste and rework to create a leaner overall lab experience. ...
(Date:2/9/2016)... ... ... i2i Systems, an early innovator and developer of population health management technology, ... report, Population Health Management 2015: How Far Can Your Vendor Take You? , ... The latest KLAS Report, leveraging over 200 user interviews, shines a light on ...
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... L top-load case packer for pouches, bags, and flow wrapped products at WestPack ... co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case packing ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... ORLANDO, Florida , February 9, 2016 /PRNewswire/ ... QIA) today announced a collaboration with 10x Genomics ... sequencing (NGS), single-cell biology and bioinformatics. --> ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QIAGEN ...
(Date:2/9/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... and heart failure, today announced that it intends to offer ... in an underwritten public offering.  The offering is subject to ... as to whether or when the offering may be completed, ... offering.   --> --> ...
Breaking Medicine Technology: